Latest Pharma Insights
The Generics Bulletin Top 50, Part Three: Industry Evolution Opens Door To New Players
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
Science Corp. First Commercial Launch Of BCI To Restore Central Vision In Germany, UK
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
Early Safety Data Show ProMIS May Have A Differentiated Anti-Amyloid Drug
Interim Phase Ib data for PMN310 show no cases of amyloid-related imaging abnormalities with edema (ARIA-E), a safety risk associated with approved drugs that requires repeat MRI monitoring.
Scrip - July 28, 2026
Interim Phase Ib data for PMN310 show no cases of amyloid-related imaging abnormalities with edema (ARIA-E), a safety risk associated with approved drugs that requires repeat MRI monitoring.
Scrip - July 28, 2026
Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication
Moving into Phase III in MASH, Altimmune's new Phase II results suggest pemvidutide may also offer commercial potential in AUD, which has several lightly utilized approved therapies but is also being targeted by Lilly and Novo Nordisk.
Scrip - July 28, 2026
Moving into Phase III in MASH, Altimmune's new Phase II results suggest pemvidutide may also offer commercial potential in AUD, which has several lightly utilized approved therapies but is also being targeted by Lilly and Novo Nordisk.
Scrip - July 28, 2026
Atea Touts Drug Interaction Profile, Shorter Treatment In Taking On Hepatitis C Giants
The company announced topline results for BEM/RZR, which offers an eight-week treatment duration, no food requirements and a favorable drug-drug interaction profile.
Scrip - July 28, 2026
The company announced topline results for BEM/RZR, which offers an eight-week treatment duration, no food requirements and a favorable drug-drug interaction profile.
Scrip - July 28, 2026
Incyte’s Opzelura Poised To Cross $1bn In Sales
The company raised financial guidance for the topical dermatology medicine based on a positive reimbursement development with the US government and an uptick in sales.
Scrip - July 28, 2026
The company raised financial guidance for the topical dermatology medicine based on a positive reimbursement development with the US government and an uptick in sales.
Scrip - July 28, 2026
Gossamer’s Seralutinib NDA Plans Intact After FDA Clears Filing Path
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026
GSK Cuts Costs With Phase III Starts Set To Double
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026
Sarepta Taps Outsider CEO As Exon-Skippers Face Key Test
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026
As Tech Stocks Tumble, AstraZeneca Reins In AI Spending
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026
Stock Watch: Why Novartis Stock Rose On Results Half As Good As J&J’s
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026
Late To The Party: Can Cipla’s Generic Advair Catch Up In The US Market?
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026
CSPC’s Novel Antidepressant Hits Mark In First-Line China Phase III Trial
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026
Chugai Fortifies Investment Function Amid Successful H1
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026
Science Corp. First Commercial Launch Of BCI To Restore Central Vision In Germany, UK
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
J&J Proposes $5.5Bn Settlement In Ovarian Talc Litigation
Johnson & Johnson has reached a $5.5bn settlement over its talc-containing products, though it is contingent upon broad plaintiff participation.
HBW Insight - July 28, 2026
Johnson & Johnson has reached a $5.5bn settlement over its talc-containing products, though it is contingent upon broad plaintiff participation.
HBW Insight - July 28, 2026
Tylenol With Naproxen Plus Market Exclusivity Added To Kenvue’s Kimberly-Clark Basket
Kenvue receives market exclusivity with FDA approval of Tylenol with Naproxen. It positions formulation not only as additional option for consumers’ OTC supplies, but also a tool in helping curb opioids abuse.
HBW Insight - July 28, 2026
Kenvue receives market exclusivity with FDA approval of Tylenol with Naproxen. It positions formulation not only as additional option for consumers’ OTC supplies, but also a tool in helping curb opioids abuse.
HBW Insight - July 28, 2026
Beauty Brand ‘AI Visibility’ Shaped by Editorial Media, Retailers
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026
The Generics Bulletin Top 50, Part Three: Industry Evolution Opens Door To New Players
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
Why SynAct Thinks Resomelagon’s Two Phase II Misses Are A Design Problem, Not A Drug Problem
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
As Blockbusters Genericize, Precision Bets Reshape The Autoimmune Pipeline
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026